We’re testing a new AI assistant to help patients, caregivers, and researchers find information faster. Click the FCF Assistant button in the lower right corner to try it.
Goals: Streamline the collection, analysis and sharing of FLC data across institutions while supporting the broader goals of open science and collaborative research within the FLC research network Principal Investigators and Partners: FCF; Velsera; Praveen Sethupathy, PhD, Cornell University; Taran Gujral, PhD, Fred Hutchinson Cancer Center Grant length: Two years Study Overview: This study intends …
Goals: Assess the potential of a FLC therapeutic vaccine to prevent disease recurrence Principal Investigators: Juliane S. Walz, MD, CCU Translational Immunology, Department of Internal Medicine Grant length: Five years Study Background and Overview: Various research efforts supported by FCF over the last 6 years have shown that immunotherapy approaches can save FLC patients’ lives. …
Grant length: Two years Study overview: Since the discovery in 2014 of the fusion gene (DNAJB1-PRKACA) that drives fibrolamellar carcinoma (FLC), a drug that would selectively inhibit or destroy the chimeric protein (DNAJ-PKAc) encoded by that gene has been considered a “holy grail” for FLC therapy. Such a drug must effectively target DNAJ-PKAc, while only …
Goal: Determine if targeting CDK7 could be a useful treatment approach for FLC. Principal Investigator: Sean Ronnekleiv-Kelly, MD Grant length: Two years, plus extension Study overview: Unregulated proliferation of cells is a hallmark of cancer. In other words, cancer cells continue to divide and increase in number when normal cells would stop dividing. A family …
Goals: Model development Principal Investigators: Aleksander Skardal, PhD Grant length: One year, plus extension Study overview: While researchers have made progress in treating fibrolamellar carcinoma (FLC), a big challenge remains – scientists do not have good lab models that mimic the real disease. Right now, there are very few FLC cell lines, patient-derived xenografts (PDX), …